Core Viewpoint - The article discusses the competitive landscape of GLP-1 drugs, focusing on East China Pharmaceutical's initiation of a head-to-head Phase III clinical trial for its dual-target drug HDM1005 against Innovent Biologics' Ma Shidu peptide, aiming to establish dominance in the diabetes and weight management sectors [4][6]. Group 1: Clinical Trial Details - East China Pharmaceutical has launched a head-to-head Phase III clinical trial for HDM1005, targeting approximately 912 patients with type 2 diabetes who have inadequate blood sugar control despite treatment with metformin or SGLT2 inhibitors [4]. - The trial design is multi-center, randomized, open-label, and includes a positive drug control, which aligns with clinical practices and reduces variability in administration frequency [4][5]. Group 2: Market Focus and Expectations - The market is particularly interested in three aspects following the initiation of the Phase III trial: the ability of HDM1005 to outperform competitors in combined endpoints of blood sugar reduction and weight loss, the profile of adverse reactions especially gastrointestinal issues and discontinuation rates, and the implications of dose escalation, adherence, and long-term benefits for commercialization [5]. - The approach taken by East China Pharmaceutical is not merely to advance a Phase III trial but to directly compete for market share in the dual-target weekly formulations for diabetes and weight management [6].